| Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins M Zajec, P Langerhorst, MM VanDuijn, J Gloerich, H Russcher, ... Clinical chemistry 66 (3), 421-433, 2020 | 56 | 2020 |
| Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow P Langerhorst, S Noori, M Zajec, YB De Rijke, J Gloerich, AJ van Gool, ... Clinical Chemistry 67 (12), 1689-1698, 2021 | 32 | 2021 |
| Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference S Noori, CPM Verkleij, M Zajec, P Langerhorst, PWC Bosman, ... Clinical Chemistry and Laboratory Medicine (CCLM) 59 (12), 1963-1971, 2021 | 19 | 2021 |
| Clonotypic features of rearranged immunoglobulin genes yield personalized biomarkers for minimal residual disease monitoring in multiple myeloma P Langerhorst, AB Brinkman, MM VanDuijn, HJCT Wessels, ... Clinical Chemistry 67 (6), 867-875, 2021 | 17 | 2021 |
| Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry S Noori, C Wijnands, P Langerhorst, V Bonifay, C Stingl, C Touzeau, ... Blood Cancer Journal 13 (1), 30, 2023 | 12 | 2023 |
| Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma EA Zaal, HJ De Grooth, I Oudaert, P Langerhorst, S Levantovsky, ... Molecular omics 18 (1), 19-30, 2022 | 12 | 2022 |
| Glycoproteomics in Cerebrospinal Fluid Reveals Brain-Specific Glycosylation Changes M Baerenfaenger, MA Post, P Langerhorst, K Huijben, F Zijlstra, ... International Journal of Molecular Sciences 24 (3), 1937, 2023 | 4 | 2023 |
| M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator C Wijnands, P Langerhorst, S Noori, J Keizer-Garritsen, HJCT Wessels, ... Clinical Chemistry and Laboratory Medicine (CCLM) 62 (3), 540-550, 2024 | 2 | 2024 |
| Minimal residual disease monitoring by targeted Mass Spectrometry allows early relapse detection in multiple myeloma S Noori, C Wijnands, P Langerhorst, S Nadal, V Bonifay, C Stingl, ... Blood 140 (Supplement 1), 2349-2350, 2022 | 2 | 2022 |
| Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow M Zajec, P Langerhorst, S Noori, M van Duijn, Y de Rijke, J Gloerich, ... BLOOD 136, 2020 | 2 | 2020 |
| N-linked glycosylation of the M-protein variable region: glycoproteogenomics reveals a new layer of personalized complexity in multiple myeloma P Langerhorst, M Baerenfaenger, P Kulkarni, S Nadal, C Wijnands, ... Clinical Chemistry and Laboratory Medicine (CCLM), 2024 | | 2024 |
| Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura T Postmus, NAG Graça, JF de Santana, B Ercig, P Langerhorst, B Luken, ... Journal of Thrombosis and Haemostasis 21 (12), 3402-3413, 2023 | | 2023 |
| B04 IMPLEMENTING M-PROTEIN DIAGNOSTICS IN MULTIPLE MYELOMA PATIENTS USING ULTRA-SENSITIVE TARGETED MASS SPECTROMETRY DATA AND AN OFF-THE-SHELF CALIBRATOR C Wijnands, P Langerhorst, S Noori, J Gloerich, V Bonifay, C Touzeau, ... HemaSphere 7 (S2), 6, 2023 | | 2023 |
| A new era in M-protein diagnostics. Personalized Mass Spectrometry based methods in a single drop of blood P Langerhorst | | 2023 |
| Precipitating Plasma RJH Martens, JFM Jacobs, P Langerhorst, FPC Boelhouwers, ... Clinical Chemistry 68 (8), 1111-1112, 2022 | | 2022 |
